Respiratory Therapeutic Devices Market to Reach USD 28.58 Billion by 2029 as Chronic Respiratory Diseases and Home-Based Care Drive Growth

Respiratory Therapeutic Devices Market Overview

The global Respiratory Therapeutic Devices Market was valued at USD 13.82 billion in 2021 and is expected to reach approximately USD 28.58 billion by 2029, expanding at a CAGR of 9.50% during 2022–2029, according to Maximize Market Research. Respiratory therapeutic devices are increasingly important in managing chronic and infectious respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), sleep apnea, and other pulmonary disorders. Rising disease prevalence, increasing geriatric populations, air pollution, lifestyle changes, and growing awareness of respiratory health are among the major factors supporting market expansion. Demand is also being strengthened by the shift toward home-based respiratory care, particularly for elderly patients and individuals requiring long-term therapy. Portable oxygen concentrators, positive airway pressure devices, nebulizers, and digitally connected respiratory equipment are creating new opportunities by enabling treatment outside traditional hospital environments. The increasing adoption of remote monitoring and connected healthcare platforms is further creating opportunities for manufacturers to combine therapeutic devices with digital services. However, high device costs and limited awareness about appropriate respiratory-device usage remain important barriers in some markets.

* Discover Profitable Growth Opportunities: https://www.maximizemarketresearch.com/request-sample/52602/

U.S. Market Trends and Investment in 2025

The United States remained a major contributor to the global respiratory therapeutic devices market, supported by advanced healthcare infrastructure, high prevalence of respiratory disorders, and strong adoption of home-care technologies. In 2025, manufacturers increasingly focused on connected respiratory care and decentralized diagnosis. ResMed announced the nationwide U.S. availability of NightOwl, an FDA-cleared home sleep apnea test, in April 2025, expanding access to simplified home-based diagnosis for obstructive sleep apnea. ResMed also acquired VirtuOx in May 2025, strengthening its virtual-care and at-home diagnostic capabilities for sleep, respiratory, and cardiac conditions. Fisher & Paykel Healthcare continued expanding its respiratory portfolio in the U.S., including the rollout of its Airvo 3 device and F&P 950 System, while investing $226.9 million in research and development during fiscal 2025. These developments highlight the industry's shift toward portable, connected, and home-centered respiratory care.

Market Segmentation: Largest-Share Segments

By Product, the Therapeutic Devices segment accounted for the largest share of the market in 2021, driven by the increasing prevalence of chronic respiratory disorders and the growing requirement for long-term respiratory therapy. Within respiratory therapeutic devices, Positive Airway Pressure (PAP) Devices represented the largest product category, supported by increasing prevalence of sleep-related disorders such as sleep apnea, insomnia, and snoring. PAP technologies, including CPAP, auto-titrating PAP, and Bi-level PAP systems, are increasingly used for long-term respiratory and sleep-disorder management.

By Region, North America dominated the global market in 2021. The region benefits from a high prevalence of respiratory diseases, a growing geriatric population, developed healthcare infrastructure, and greater awareness of advanced respiratory treatment technologies.

Respiratory Therapeutic Devices Market Key players:
• CareFusion Corporation
• Covidien plc (Medtronic plc)
• Drägerwerk AG
• Fisher & Paykel Healthcare
• GE Healthcare
• Inogen
• MAQUET Holding B.V. & Co. KG (Getinge Group)
• Nihon Kohden Corporation.
• Philips Respironics
• Siemens Healthcare
• Smiths Medical
• Chart industries
• Compumedics Ltd.
• Invacare
• Mindray
• Masimo.
• F. Hoffmann-La Roche Ltd
• Bayer AG
• Rotech Healthcare Inc.
• ACare Technology

Competitive Analysis

The MMR report identifies CareFusion Corporation, Covidien plc (Medtronic plc), Drägerwerk AG, Fisher & Paykel Healthcare, and GE Healthcare among the key companies in the global respiratory therapeutic devices market. The report does not disclose verified individual market-share percentages for these companies, so exact shares are not stated.

CareFusion Corporation is part of BD and has an established presence in respiratory care and ventilation technologies. Its respiratory portfolio and clinical-care solutions support hospitals and healthcare providers managing patients requiring assisted ventilation and respiratory therapy.

Covidien plc, now part of Medtronic, remains an important respiratory-care technology provider through Medtronic's portfolio of ventilators and respiratory-care solutions. Medtronic continues to focus on technologies that support critical-care ventilation and patient management, strengthening opportunities as hospitals modernize respiratory-care infrastructure.

Drägerwerk AG continues to develop advanced ventilation and respiratory-care systems for intensive-care environments. Its technology portfolio emphasizes patient-specific ventilation, monitoring, and integration of respiratory information into clinical workflows, supporting demand for advanced hospital respiratory systems.

Fisher & Paykel Healthcare strengthened its respiratory-care portfolio during 2025. The company invested $226.9 million in R&D in fiscal 2025, while expanding the U.S. rollout of the F&P Airvo 3 and F&P 950 System. Its Homecare product group generated $739.9 million in revenue in fiscal 2025, up 13% from the previous year, demonstrating continued demand for home respiratory and sleep-care products.

GE Healthcare maintains a broad respiratory-care portfolio spanning critical-care ventilation and patient monitoring. Its CARESCAPE R860 ventilator is designed for critical-care environments, combining ventilation capabilities with monitoring and clinical support tools.

Regional Analysis

United States: The U.S. is a major contributor to North America's leading position in the global respiratory therapeutic devices market. High disease prevalence, advanced medical infrastructure, strong home-care adoption, and increasing investment in digital respiratory technologies support continued growth.

Germany: Germany represents an important European market because of its developed healthcare system, aging population, and demand for advanced hospital respiratory equipment. The country's established medical-device industry also supports adoption of innovative ventilation and respiratory technologies.

Japan: Japan's rapidly aging population and high demand for long-term healthcare create opportunities for respiratory therapeutic devices, particularly portable and home-use technologies. Growing emphasis on managing chronic conditions outside hospitals further supports market development.

China: China's expanding healthcare infrastructure, large patient population, rising respiratory-disease burden, and increasing availability of advanced medical equipment create substantial long-term opportunities for respiratory therapeutic-device manufacturers.

Proton Therapy Market https://www.maximizemarketresearch.com/market-report/proton-therapy-market/228949/

Rotavirus Vaccine Market https://www.maximizemarketresearch.com/market-report/rotavirus-vaccine-market/231929/

Conclusion

The global Respiratory Therapeutic Devices Market is projected to reach USD 28.58 billion by 2029, reflecting sustained demand for technologies that address chronic respiratory and sleep-related disorders. In our view, the strongest growth opportunities will emerge from the convergence of portable respiratory devices, home healthcare, digital monitoring, connected therapy, and personalized treatment. The continued rise in COPD, asthma, sleep apnea, and other respiratory conditions will expand the underlying patient base, while technological advances can make long-term treatment more convenient and accessible. Investments in connected devices, remote patient monitoring, home diagnostics, lightweight oxygen systems, and intelligent ventilation are expected to remain key factors influencing the market's future expansion.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? [email protected]

City Of Articles